[Respiratory care in spinal muscular atrophy in the new therapeutic era]

Area of Science:

• Neurology
• Genetics
• Pediatrics

Background:

• Spinal muscular atrophy (SMA) is a leading inherited cause of infant mortality.
• Respiratory complications, including pneumonia and insufficiency, are the most severe in SMA patients.
• SMA presents in four subtypes based on onset and motor function.

Purpose of the Study:

• To highlight the importance of informed parental decisions in managing SMA.
• To outline current respiratory management strategies for SMA.
• To emphasize the need to optimize preventive respiratory care in the context of new SMA treatments.

Main Methods:

• Review of current respiratory management practices for SMA.
• Consideration of emerging treatments like nusinersen, gene therapy, and others.
• Discussion on the integration of new standards of care for respiratory management.

Main Results:

• Current respiratory management involves cough assistance, preventing lung underdevelopment, treating infections, and managing swallowing issues, reflux, and malnutrition.
• Nusinersen, a nonsense oligonucleotide, is the first FDA and EMA-approved specific treatment for SMA.
• Gene therapy and other treatments are under development, indicating a evolving therapeutic landscape.

Conclusions:

• Optimizing preventive respiratory management is essential with the advent of new SMA therapies.
• A multidisciplinary approach is necessary to address the complex respiratory needs of SMA patients.
• The integration of novel treatments requires an updated standard of care for respiratory management in SMA.